Autologous saphenous vein is commonly used as a conduit to bypass atherosclerotic lesions in coronary and femoral arteries. Despite the wide use of arterial conduits, which are less susceptible to complications and failure, as alternative conduits, the saphenous vein will continue to be used in coronary artery bypass grafting until acceptable alternative approaches are evaluated. Hence, preservation of vein graft patency is essential for the long-term success. Gene therapy is attractive in this setting as an ex-vivo technology to genetically manipulate the conduit before grafting. The use of safe and efficient vectors for delivery is a necessity as well as a strategy to improve patency in the long term. Here, we review the current clinical practice, the pathogenesis of bypass graft failure and adenovirus-mediated gene therapy strategies designed to improve late vein graft failure by modulation of smooth muscle cells in the vein wall.
CLINICAL USE OF AUTOLOGOUS SAPHENOUS VEIN
Autologous saphenous vein is used as a conduit to bypass atherosclerotic lesions both in the coronary artery (coronary artery bypass grafting (CABG)) [1] [2] [3] [4] and in femoral arteries (infrainguinal bypass graft surgery). Even with the rapid development of intracoronary stents, certain advantages of CABG over percutaneous coronary intervention (PCI) are likely to continue in the foreseeable future, particularly in diabetic patients and in those with left main and multivessel coronary diseases. 5 The autologous saphenous vein remains a widely used conduit for CABG ( Figure 1) ; however, late vein graft failure is the Achilles' heel of this operation. Nearly, half of the patients may require reoperation 10-15 years after CABG to alleviate symptoms and treat vein graft occlusion. 2, 5 In the United States alone, the estimated direct and indirect cost in treating coronary heart disease was more than US$177 billion in 2010. 6 To date, despite a very large number of clinical trials, apart from lipid-lowering drugs, 7 no other pharmacological agents appear effective in preventing early vein graft remodelling or subsequent accelerated atherosclerosis. As such, the fate of vein grafts remains largely unchanged even after decades of technical development. Some recent observations indicated that the vein graft patency rates may be very poor. For instance, in the PREVENT IV trial, 8 1829 patients had follow-up angiography 12-18 months after CABG that showed per-patient vein graft failure rate was 445% (each patient had at least two vein grafts), while per-graft vein graft occlusion rate was 426%. In the latest ROOBY trial, 9 the incidence of vein graft occlusion during the first postoperative year in 894 patients was 414% (following conventional harvesting) or up to 25% (following endoscopic harvesting). Such failure rates are similar to those reported in 1996 by Fitzgibbon et al. 3 Knowledge about the pathophysiology of vein graft failure has significantly enhanced recently (this is discussed in detail below). Furthermore, distal coronary 'run-off' can affect the long-term vein graft patency. [10] [11] [12] As the severity of disease in the native coronary recipient artery increases, distal run-off may reduce. In the Radial Artery Patency and Clinical Outcomes (RAPCO) trial, saphenous vein graft patency (measured by the protocol-directed angiograms) was demonstrated in 80% of subjects at 9 years. 11 However, on closer examination it is apparent that one of the predictors of vein graft patency was an anastomosis with the left anterior descending coronary artery, which is now rarely performed. The initial calibre of the recipient coronary artery (that is, a diameter of at least 2 mm) is another predictor of long-term graft patency. 12 In a recent randomised controlled trial conducted at 11 Veterans Affairs medical centres in United States undergoing first-time elective CABG, 13 the 1-year graft patency of the radial artery conduits was not significantly greater than venous grafts. In fact, the 7-year patency rates for the vein grafts were also similar to the radial artery conduits in a randomised Australian trial 11 as well as in a retrospective French series with 20-year follow-up. 14 The relevance of vein graft failure, therefore, should not be overlooked.
Given the large number of CABG patients living with late vein graft failure, and the complexities of their clinical management, their cardiac morbidity and mortality is an increasing challenge for primary and secondary care clinicians. When revascularisation is performed in CABG patients, acute and long-term outcomes are much worse than in patients without prior CABG. 15 PCI in redo CABG carries a fourfold higher risk of death compared with the index procedure. 15 Patients with recurrent angina after CABG are usually elderly and co-morbid health problems are very common. [16] [17] [18] Redo CABG is uncommon and only performed in o2% of invasively managed acute coronary syndrome patients. 17 In the United Kingdom, of 161 patients who had PCI 126±65 months after CABG, cardiac death, myocardial infarction or repeat PCI occurred in 14% of them by 13 months (mainly related to repeat PCI (12%)). In the United Kingdom overall, of the 33 652 PCIs performed in 1999/2000, 907 (2.7%) occurred in patients with prior CABG. Only 1 in 10 procedures was reported as successful and 1.3 and 1.0% of patients experienced in-hospital myocardial infarction or death, respectively. 19 Ten years on 2009/ 2010, 8.4% of all patients undergoing PCI had a history of prior CABG and procedure-related outcomes remained disappointingly similar (1 in 10 procedural success, in-hospital death rate (1.0%) and 30-day mortality (1.5%)).
By contrast secondary prevention drug therapies have beneficial effects in symptomatic patients with prior CABG. [20] [21] [22] [23] In contrast to clinical trials involving revascularisation, patients with prior CABG are usually not excluded from drug trials and the evidence for secondary prevention medical therapies in patients with prior CABG is fairly robust. In acute coronary syndrome patients with prior CABG, health outcomes are also improved by treatment with anti-platelet drug therapies. [21] [22] [23] Furthermore, new evidence-based medicines continue to emerge including more potent anti-platelet drugs such as prasugrel 24 and ticagrelor 25 and safer anti-coagulants, such as fondaparinux. 26 However, to a great extent, these treatments have mainly palliative effects in patients with progressive vein graft disease and more definitive preventative strategies are needed to prevent vein graft disease occurring in the first place.
PATHOGENESIS OF VEIN GRAFT DISEASE
Detailed studies using mainly pre-clinical in-vivo models have enabled us to construct an approximate timeline of the events that occur in vein grafts and ultimately lead to reduced patency ( Figure 2 ). Immediately after implantation of the vein as a graft into the arterial circulation a complex series of biological events is initiated in the vein. Within the first few days after implantation many vein grafts fail due to thrombosis, stimulated by endothelial injury. 27 Additionally, in the first 24 h vein grafts undergo a period of ischaemia followed by Figure 2 Processes involved in vein graft failure. Damage to the endothelium leads to thrombosis formation and early vein graft failure. Late vein graft failure is predominantly due to intimal thickening and superimposed atherosclerosis. Vessel wall damage and ischaemia lead to inflammation and vessel wall remodelling and intimal thickening.
Opportunities for vein graft gene therapy S Wan et al reperfusion, resulting in the generation of superoxide and other reactive oxygen species that trigger cytotoxicity of endothelial and vascular smooth muscle cells (VSMCs). 28, 29 The grafted vein is then targeted by an acute inflammatory response involving neutrophil and mononuclear cell recruitment and oxidative stress persists. 28 Extracellular matrix (ECM) remodelling and migration of medial VSMCs into the intima occurs within the first week after implantation. Once in the intima the VSMCs proliferate at a heightened rate and deposit newly synthesised ECM, thereby contributing further to the intimal thickening (for a review, see Newby 30 ). The resultant thickened intima is highly susceptible to superimposed accelerated atherosclerosis due to the infiltration of monocytes that differentiate into macrophages and develop into foam cells after lipid uptake (for a review, see Schwartz et al. 31 ). The resultant lesions within the vein graft are diffuse, concentric, friable plaques with poorly developed or absent fibrous caps. 32, 33 The surgical preparation of saphenous veins for the surgical procedure causes considerable removal of the endothelium 34 and a 'no touch' surgical preparation of the vein leads to superior vein graft patency. 35 Endothelial denudation allows platelet and leukocyte adhesion immediately after graft implantation that precipitates thrombosis, as well as acting as an initiating factor for intimal thickening. [36] [37] [38] [39] Adherent (activated) platelets generate a large number of substances, including thromboxane A 2 , endothelin-1, serotonin, platelet-derived growth factor, platelet factor IV, fibrinogen, fibronectin, thrombospondin, von Willebrand factor, b-thromboglobulin and reactive oxygen species, which activate VSMCs in the medial layer of the vein graft. Activated VSMCs are more synthetic and have heightened proliferation and migration rates (for a review, see Owens et al. 40 ). As a result, VSMCs migrate from the media into the intima where they proliferate and deposit ECM, leading to the thickening of the intimal layer. Moreover, coagulation factors and fibrinolysis products are also important factors that contribute to VSMC activation and intimal thickening (for a review, see Jeremy et al. 41 ).
Enhanced leukocyte binding is enabled due to increased adhesion molecule expression within the vein graft after implantation. 42, 43 Consequently, soluble forms of the adhesion molecules such as vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 have been proposed as potential inhibitors of vein graft disease. 44 Leukocytes (neutrophils and monocytes) also participate in the induction of intimal thickening in the vein graft. [37] [38] [39] Adherent leukocytes, particularly neutrophils, release numerous pro-inflammatory substances, including leukotrienes, interleukins, histamine, tumour necrosis factor, platelet activating factor and proteases, all of which promote VSMC proliferation and migration (for a review, see Segel et al. 45 ). Monocyte adhesion also occurs early after vein graft implantation and promotes intimal thickening. 46 Monocytes invade into the intima and differentiate into resident macrophages that transform into the foam cells, after uptake of lipid, which are a major contributor to atherogenesis. Similarly to adherent leukocytes, macrophages release a plethora of factors that promote intimal thickening including proteases such as matrix-degrading metalloproteinases (MMPs), growth factors, cytokines and reactive oxygen species.
Endothelial denudation also results in the loss of vasculoprotective systems (principally nitric oxide (NO) and prostacyclin as well as heparin-like substances) that inhibit thrombosis and inflammation. The loss of these systems permits thrombosis and inflammation within the vein graft and renders the graft prone to intimal thickening and subsequent atherogenesis. Moreover, in addition to the inhibition of platelet and leukocyte adhesion, NO, prostacyclin and heparin-like substances inhibit other processes that contribute to intimal thickening such as VSMC proliferation and migration and protease expression (for a review, see Ramli et al. 47 ).
The endothelial lining of the vein graft is in fact repaired within 1-2 weeks as a result of proliferation and migration of endothelial cells 48 and this is thought to repress thrombogenicity and intimal thickening. 49 The repaired endothelial lining is however markedly dysfunctional in part due to the arterial pressure that the vein is now subjected to. 50, 51 After implantation, the vein graft, which has been subjected only to an internal pressure of 10 mm Hg in the venous circulation, is immediately subjected to the arterial pressure (100 mm Hg) as well as immediate increases in flow, longitudinal wall (shear) stress, circumferential, radial and pulsatile deformation and stress. 52 Numerous genes are upregulated in response to the altered shear stress, including adhesion molecules, 53, 54 and therefore this is a substantial promoter of intimal thickening. Since the wall of the saphenous vein graft is considerably thinner than the recipient artery and lacks connective and elastic tissue layers that characterises arteries, it undergoes an adaptation to the arterial environment by thickening or 'remodelling' , possibly to resist the altered haemodynamic stresses. This predominantly involves VSMC proliferation and deposition of ECM. 55, 56 This process of vein graft remodelling also intrinsically alters intragraft haemodynamics. The growth of the graft is asymmetric that may also promote chaotic blood flow patterns, 57 resulting in enhanced platelet and leukocyte adhesion, and thrombosis that in turn can augment intimal thickening.
The blood vessel wall is a highly organised structure of cells and ECM ( Figure 3 ; for a review, see Adiguzel et al. 58 ). The ECM is synthesised by the VSMCs within the arterial wall, which then interacts with the VSMCs through cell-to-matrix contacts via integrins. In the medial layer of the blood vessel wall, VSMCs are surrounded by basement membrane, which is in turn embedded in fibrillar collagens type I, III and V, collagen type XVIII, elastin, fibronectin and glycoproteins including proteoglycans and cartilage oligomeric matrix protein (thrombospondin 5). Contact of VSMCs with the ECM via integrins retards VSMC migration and proliferation (for a review, see Newby 59 ). More recently, it has been established that cell-to-cell contacts via cadherins also retard VSMC proliferation. 60, 61 To enable VSMC migration and proliferation the ECM and cadherin contacts must be digested by proteases including MMPs (for a review, see Newby 59 ). Upregulation and activation of MMPs occurs as a result of surgical preparation of the saphenous vein, and during intimal thickening in human organ cultures and experimental vein grafts. 62, 63 Furthermore, direct proof of the involvement of MMPs in vein graft intimal thickening has been provided by the observation that overexpression of the endogenous MMP inhibitors tissue inhibitors of MMPs (TIMPs) significantly retarded intimal thickening. [64] [65] [66] [67] Overproduction 68 ). Consequently, the regeneration of the vasa vasorum may constitute an important adaptation of vein grafts to arterial conditions and to repair and reintegration of the microvascular system. Support for this suggestion is gained from the observation that in vein grafts subjected to external stenting increased formation of adventitial microvessels occurs concurrently with reduced intimal thickening. 72 
OPPORTUNITIES FOR GENE THERAPY IN BYPASS GRAFTING
Despite a very large number of clinical trials, no specific pharmacological agents appear to have beneficial effects on early vein graft remodelling or subsequent accelerated atherosclerosis. For this reason, alternative and novel therapeutic strategies are urgently required. Accordingly, a number of gene transfer strategies, using specific genes delivered intraoperatively to either limit VSMC proliferation or inflammation, or to improve endothelial function, appear to be effective pre-clinically. The E2F decoy oligonucleotide approach from the Dzau laboratory using pressure-mediated delivery of 'decoy oligonucleotides' to prevent E2F-mediated transcription of pro-proliferative genes to promote vein 'arterialisation' failed in late clinical trials (PREVENT) for both coronary and peripheral grafts, despite encouraging pre-clinical and phase I/II trial data. 48, [73] [74] [75] [76] This highlights a number of important issues, including the possible lack of utility of the anti-proliferative strategy in the human setting, the potential limitations in the decoy approach, the delivery methodology and (possibly) the limitations of animal models utilised for pre-clinical studies. Further research into decoy oligonucleotides has been conducted recently. 77 A strategy to decoy Egr-1 was employed in a rabbit model of vein graft interposition grafts using a single intraoperative approach. Multiple time points were tested after intervention (acute and chronic). The authors found that a 60% inhibition of Egr-1 was achieved with a concomitant decrease in cellular proliferation and the study found a reduction in intimal thickness for the Egr decoy-treated samples compared with controls. 77 This demonstrates that alternative decoys may hold value in the setting of vein graft neointima formation but assigning differences between the Egr-1 approach and the E2F approach already tested clinically would be important for translational aspirations.
To date, no clinical gene therapy studies in the bypass graft setting have been conducted. Opportunities
VECTORS FOR GENE DELIVERY TO BYPASS GRAFTS
Delivery of the therapeutic gene must occur within CABG surgery. The 'clinical window' is short. Vector systems thus must be efficient to achieve efficient gene transfer into the target graft within the window of access. Many delivery systems have been evaluated and tested using both reporter gene systems and therapeutic transgenes-these include both viral and non-viral vectors, the latter more efficient in general due to the higher level of cell gene transfer that can be achieved in general. Adenovirus (Ad)-based vectors have become the most favoured vectors for this task, albeit they come with some limitations and have not yet been tested at the clinical level in the context of vein graft gene therapy. Ad is, however, a relatively efficient vector for gene delivery to the vein. Pivotal studies in the 1990s described the role of the coxsackie and adenovirus receptor and integrins in adenovirus type 5 (Ad5) gene transfer. 78, 79 The interaction with coxsackie and adenovirus receptor tethers the virus to the cell surface with subsequent engagement of the penton base RGD motif with integrins to mediate cellular internalisation. However, the mechanism for gene transfer by Ad is not clear since coxsackie and adenovirus receptor expression is not evident on VSMCs. 80, 81 Early studies in the vasculature showed detrimental effects of Ad vectors to the vasculature following the gene transfer. For example, some early studies showed enhanced neointima formation following arterial gene transfer in rabbits as well as high levels of inflammatory markers on endothelium; 82 however, we recently reported that there was no difference in inflammatory markers in long-term pig grafts using Ad5 vectors. 67 This may represent differences in responses in different models (rabbit/pig) and potential differences in virus quality control. Clearly, modulation of virus infection to maintain/improve target cell infection within the constraints imposed in the vein graft gene therapy setting would be advantageous. Especially important are (1) considerations for maximal uptake into target cells within short time periods allowed for access to the vein clinically, (2) reduction in the ability of human sera to neutralise Ad5 through pre-existing immunity in many patients 83 via specific modification of the Ad5 capsid or use of alternate serotypes (although this may alter the efficiency of vascular gene delivery), (3) use of helper-dependent Ad systems to provide longer term gene therapy in the vasculature should this be a requirement. 84 
STUDIES USING GENE THERAPY FOR VEIN GRAFTS
The majority of strategies for prevention of late vein graft failure have focused on phenotypic modulation of the vessel wall, assessing proliferation, migration and apoptosis. These aspects have been discussed previously 85 and reviewed recently in the context of graft pathophysiology 86 and here we bring the literature up to date with recent original papers in this area. It has recently been demonstrated that NogoB is a novel regulator of the vascular system 87 and that NogoB overexpression using the Ad5 approach significantly reduced neointima formation in pig venous grafts. 88 An interesting recently published study 89 focused on the concept that overexpression of cyclooxygenase-1 might attenuate vein graft disease. The authors utilised an Ad approach in rabbit jugular veins and assessed parameters at 4 weeks post grafting. It was shown that blood flow in cyclooxygenase-1-treated vein grafts increased as well as in the lumen area. Functional effects of cyclooxygenase-1 were observed when assessed at 72 h. This demonstrates the benefit of short-term Ad-mediated overexpression of relevant genes. In a rabbit model, but using a different strategy, the effect of platelet-derived endothelial cell growth factor gene transfer has also been evaluated. 90 This strategy used polaxmer hydrogel at 20% to deliver plasmid DNA to the adventitia of rabbit grafts in the presence of trypsin to further enhance gene transfer. A significant reduction in neointima formation was observed at both 2 and 8 weeks post grafting, primarily through an anti-proliferative effect achieved through elevation of haemoxygenase-1 mediated by therapeutic gene transfer. 90 Since inflammation is also a key factor in vein graft disease, chemokine receptor-2 has emerged as an effector of vein graft pathology. Using a mouse model, a lentivirus expressing shRNA to chemokine receptor-2 was evaluated. This intervention led to a reduction in chemokine receptor-2 levels and a 38% reduction in graft thickening, highlighting the potential of this knockdown strategy and also the power of lentivirus vectors. 91 However, production of these vectors for assessment in larger animal models and ultimately in man would be challenging but could be considered as an important aim to achieve.
As discussed previously, 85 the proteolytic system has a prominent role in vein graft disease. A recent study developed an intriguing system to probe this in the mouse in-vivo and human ex-vivo models. The authors developed a chimeric gene consisting of the receptor binding amino terminal fragment of urokinase-type plasminogen activator and bovine trypsin inhibitor linked to TIMP-1. Delivery of this vector blocked neointima formation in both models. 92 Targeting the TGFb system is also proven to be a popular approach recently. Using a series of adenoviruses and the human ex-vivo model, it was reported that fibromodullin was superior to decorin overexpression in reducing neointimal area and thickness in human saphenous vein segments at 14 days. 93 An alternate approach using Activin A to alter the contractile properties of VSMCs, led to a reduction in neointimal parameters in a rat model. 94 Therefore, there remains a number of strategies of potential benefit to the prevention of vein graft disease. Our focus has been on utilising the properties of TIMP-3. TIMP-3, a member of the tissue inhibitors of metalloproteinase family, has the ability to block both VSMC migration and promote apoptosis, the latter requiring high concentrations of TIMP-3. 95 First-generation Ad5-mediated overexpression of TIMPs reduced neointimal formation in a human in-vitro model of vein graft failure and ex-vivo adenoviral. 66 It is important to note that Ad-mediated overexpression of TIMP-3 leads to high levels of matrixassociated TIMP-3 around the VSMCs closest to lumen of the vessel. It is likely that this provides an effective barrier to migration of the VSMCs. In addition, VSMC apoptosis was observed but this occurred only where high concentrations of TIMP-3 were observed and not randomly throughout the vessel wall. 66 We have recently performed longer term experiments in a pig vein graft model and shown sustained efficacy out to 3 months post gene transfer. 67 This is important since it illustrates that short-term transgene overexpression leads to lasting effects on neointima formation. Taken together with other studies, this presents a new opportunity to treat late vein graft failure using an Ad gene therapy approach and is a goal that we are aiming to test clinically in the future.
